Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Lennart TonneijckMarcel H A MuskietMark M SmitsPetter BjornstadMark H H KramerMichaela DiamantEwout J HoornJaap A JolesDaniel H van RaaltePublished in: Diabetes, obesity & metabolism (2018)
Immediate exenatide infusion increases UEUA in overweight healthy men and in T2DM patients, probably by inhibiting Na+ /H+ -exchanger type-3 in the renal proximal tubule. Prolonged treatment with a long-acting or short-acting GLP-1RA does not affect plasma UA or UEUA in T2DM patients with normal plasma UA levels and at relatively low cardiovascular risk. Our results suggest that the cardio-renal benefits of GLP-1RA are not mediated through changes in UA.
Keyphrases
- uric acid
- clinical trial
- end stage renal disease
- rheumatoid arthritis
- metabolic syndrome
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- disease activity
- ankylosing spondylitis
- randomized controlled trial
- body mass index
- adipose tissue
- weight gain
- systemic sclerosis
- skeletal muscle
- patient reported
- insulin resistance
- patient reported outcomes
- middle aged
- idiopathic pulmonary fibrosis
- double blind
- replacement therapy